EDEN news

iShares MSCI Denmark · Europe

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Quartz · 28 Oct 2026, 17:20 UTC
Lilly's retatrutide more than doubled Ozempic weight loss in trial
20.8% of EDEN
Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
20.8% of EDEN
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
20.8% of EDEN
www.theepochtimes.com · 28 Oct 2026, 00:00 UTC
Judge Declines to Block Eli Lilly Weight-Loss Drug Ads in Dispute With Novo Nordisk
20.8% of EDEN
Where to buy EDEN
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 27 Oct 2026, 22:08 UTC
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) | Seeking Alpha
20.8% of EDEN
Quartz · 27 Oct 2026, 11:29 UTC
Judge rejects Novo Nordisk bid to block Eli Lilly weight-loss ads
20.8% of EDEN
Where to buy EDEN
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Benzinga · 27 Oct 2026, 10:51 UTC
Novo Nordisk Loses Court Bid Against Eli Lilly's Weight-Loss Drug Ads -- Judge Says Sales Impact Was Negli
20.8% of EDEN
Market Screener · 27 Oct 2026, 05:31 UTC
Novo Nordisk denied injunction against Eli Lilly's advertising
20.8% of EDEN
Bloomberg Business · 26 Oct 2026, 20:53 UTC
Novo Nordisk Loses Court Ruling Over Eli Lilly Obesity Drug Ads
20.8% of EDEN
Reuters · 26 Oct 2026, 20:05 UTC
US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk
20.8% of EDEN
Seeking Alpha · 28 Oct 2026, 21:30 UTC
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript | Seeking Alpha
4.7% of EDEN
FXStreet · 28 Oct 2026, 07:43 UTC
Euro: Fed rate outlook and ECB credit signals in focus - Danske Bank | FXStreet
7.0% of EDEN
Aol · 28 Oct 2026, 19:44 UTC
Genmab Stock Hits 52-Week High - Here's Why
4.7% of EDEN
RTTNews · 28 Oct 2026, 19:16 UTC
Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
4.7% of EDEN
Benzinga · 28 Oct 2026, 17:44 UTC
Genmab Stock Hits 52-Week High - Here's Why - Genmab (NASDAQ:GMAB)
4.7% of EDEN
RTTNews · 28 Oct 2026, 15:52 UTC
Genmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial Data
4.7% of EDEN
Bloomberg Business · 28 Oct 2026, 14:28 UTC
Genmab Shares Hit Record as Cancer Trial Extends Drugmaker's Run
4.7% of EDEN
Seeking Alpha · 28 Oct 2026, 14:10 UTC
Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ) | Seeking Alpha
4.7% of EDEN
wallstreet:online · 28 Oct 2026, 13:45 UTC
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
4.7% of EDEN
Investing.com · 26 Oct 2026, 08:58 UTC
Why is Genmab stock surging today? By Investing.com
4.7% of EDEN